Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C33H34N4O6 |
Molecular Weight | 582.6463 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)OC(=O)C1=C(C)NC(N)=C([C@H]1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OC3CN(C3)C(C4=CC=CC=C4)C5=CC=CC=C5
InChI
InChIKey=ZKFQEACEUNWPMT-NDEPHWFRSA-N
InChI=1S/C33H34N4O6/c1-20(2)42-32(38)27-21(3)35-31(34)29(28(27)24-15-10-16-25(17-24)37(40)41)33(39)43-26-18-36(19-26)30(22-11-6-4-7-12-22)23-13-8-5-9-14-23/h4-17,20,26,28,30,35H,18-19,34H2,1-3H3/t28-/m0/s1
Molecular Formula | C33H34N4O6 |
Molecular Weight | 582.6463 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Azelnidipine is a dihydropyridine calcium channel antagonist being jointly developed by Daiichi Sankyo Inc (formerly Sankyo) and Ube Industries. Azelnidipine is a L-type calcium channel antagonist. Azelnidipine was approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on Jan 31, 2003. Azelnidipine is indicated for the treatment of hypertension. Its trend name is Calblock. Azelnidipine has two enantiomers (R-(−)- and S-(+)-enantiomers) due to an asymmetric carbon at the 4-position, and the (R)-(−) enantiomer of dihydropyridine calcium antagonists is considered to possess intrinsic pharmacological activity. The
pharmacological action of azelnidipine resides in the (R)-enantiomer. This is in marked contrast to other calcium channel blocker (CCB) in which the (S)-enantiomer is responsible for the biological activity. There were no
significant differences in the inhibitory effects on TGF-b1-induced expression of COL1A1 mRNA among vitamin E - pretreated LX-2 cells
treated with azelnidipine (racemate), (R)-(-)-azelnidipine
or (S)-(+)-azelnidipine, although the L-type
voltage-operated calcium channel blocking activity of (R)-(-)-
enantiomer was more potent than that of the (S)-(+)-
enantiomer.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Calblock Approved UseAs a calcium channel antagonist, this medicine relaxes blood vessels in order to lower blood pressure. It is usually used to treat hypertension. Launch Date1.04397118E12 |
Sample Use Guides
The normal dose for an adult is 8-16 mg of azelnidipine once daily, taken orally after breakfast. The maximum dosage is 16 mg/day. The initial dosage is to be 8 mg/day or less, to be adjusted as symptoms are monitored, up to 16 mg daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21790536
Treatment with 10 ng·mL-1 TGF-b1 or 50 uM Ang II increased
[Ca]i, and all calcium blockers at 100 nM, with the exception
of (S)-(+)-azelnidipine, significantly reduced the TGF-b1-
induced increase in [Ca]i.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:48:25 UTC 2023
by
admin
on
Sat Dec 16 09:48:25 UTC 2023
|
Record UNII |
368RN01P1M
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
722455-09-6
Created by
admin on Sat Dec 16 09:48:25 UTC 2023 , Edited by admin on Sat Dec 16 09:48:25 UTC 2023
|
PRIMARY | |||
|
45107611
Created by
admin on Sat Dec 16 09:48:25 UTC 2023 , Edited by admin on Sat Dec 16 09:48:25 UTC 2023
|
PRIMARY | |||
|
368RN01P1M
Created by
admin on Sat Dec 16 09:48:25 UTC 2023 , Edited by admin on Sat Dec 16 09:48:25 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
RACEMATE -> ENANTIOMER |